Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Viatris Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.69 (market cap $157.51B), while Viatris Inc trades at $16.16 (market cap $18.69B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 8.4× Viatris Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| BBVA | VTRS | |
|---|---|---|
Market Cap | $157.51B | $18.69B |
Sector | Financials | Health |
52-Week High | $28.50 | $17.86 |
52-Week Low | $17.96 | $9.49 |
Dividend Yield | 3.8% | 2.95% |
Enterprise Value | — | $30.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.35 with a bullish technical outlook, supported by moving averages and a strong ADX trend indicator. The company reported robust Q2 2026 earnings, beating EPS estimates with $0.63 actual versus $0.59 expected, driven by loan growth and a new $2.3 billion share buyback announcement. Revenue reached $39.42 billion in 2025, with net income of $10.51 billion and a rising profit margin of 26.66%.
Outlook remains positive with analyst consensus leaning buy (53.85%) and a projected revenue increase to $42.5 billion in 2026. Key risks include regulatory probes in Spain and volatile cash flow trends, but strong profitability and institutional support suggest upside potential for investors seeking European bank exposure.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
